​

GSK (GSK) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

GSK Stock Forecast

GSK (GSK) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $53.00, with a high of $53.00 and a low of $53.00. This represents a -2.36% decline from the last price of $54.28.

$30 $35 $40 $45 $50 $55 High: $53 Avg: $53 Low: $53 Last Closed Price: $54.28

GSK Stock Rating

GSK stock's rating consensus is Hold, based on 29 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (31.03%), 16 Hold (55.17%), 4 Sell (13.79%), and 0 Strong Sell (0.00%).

Hold
Total 29 0 4 16 9 Strong Sell Sell Hold Buy Strong Buy

GSK Price Target Upside V Benchmarks

TypeNameUpside
StockGSK-2.36%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks1.85%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$44.13
Last Closing Price$54.28$54.28$54.28
Upside/Downside---18.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-161-8
Feb, 261151-8
Jan, 261151-8
Dec, 251151-8
Nov, 25124119
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2025Wan NurhayatiCFRA$53.00$46.6713.56%-2.36%
Apr 15, 2025Peter VerdultBNP Paribas$35.25$35.68-1.21%-35.06%
Jul 02, 2024Peter WelfordJefferies$53.00$38.3838.09%-2.36%
Apr 11, 2024Vamil DivanGuggenheim$36.00$40.69-11.53%-33.68%
Apr 11, 2024Mark PurcellMorgan Stanley$85.00$40.69108.90%56.60%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 20, 2026BarclaysUnderweightUnderweighthold
Feb 09, 2026CitigroupNeutralNeutralhold
Feb 09, 2026Cowen & Co.HoldHoldhold
Jan 27, 2026CitigroupBuyNeutralinitialise
Jan 16, 2026Deutsche BankHoldHoldhold
Jan 14, 2026Morgan StanleyUnderweightUnderweighthold
Jan 06, 2026BarclaysEqual-WeightUnderweightdowngrade
Dec 10, 2025HSBCReduceReducehold
Nov 25, 2025Bank of America SecuritiesNeutralupgrade
Apr 15, 2025Exane BNP ParibasNeutralinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.19$2.41$1.20-----
Avg Forecast$2.23$2.68$3.04$3.07$3.25$3.65$3.98$4.06
High Forecast$2.28$2.76$3.11$3.23$3.37$4.12$4.19$4.21
Low Forecast$2.18$2.59$2.91$2.93$3.12$1.99$3.73$3.91
Surprise %-1.79%-10.07%-60.53%-----

Revenue Forecast

$25B $30B $35B $40B $45B $50B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.11B$29.32B$30.33B-----
Avg Forecast$46.08B$35.57B$37.78B$38.70B$40.25B$42.50B$44.48B$45.07B
High Forecast$46.92B$36.42B$38.12B$39.69B$40.92B$43.74B$45.77B$46.39B
Low Forecast$45.31B$34.63B$37.42B$37.19B$38.96B$41.25B$43.17B$43.75B
Surprise %-25.98%-17.55%-19.72%-----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.38B$4.92B$4.93B-----
Avg Forecast$9.15B$11.01B$12.36B$12.66B$13.33B$12.56B$16.26B$16.69B
High Forecast$9.37B$11.35B$12.78B$13.28B$13.84B$16.93B$17.21B$17.32B
Low Forecast$8.95B$10.63B$11.95B$12.05B$12.82B$8.20B$15.32B$16.06B
Surprise %-52.08%-55.31%-60.14%-----

GSK Forecast FAQ

Is GSK stock a buy?

GSK stock has a consensus rating of Hold, based on 29 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 16 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that GSK is a neutral investment for most analysts.

What is GSK's price target?

GSK's price target, set by 29 Wall Street analysts, averages $53 over the next 12 months. The price target range spans from $53 at the low end to $53 at the high end, suggesting a potential -2.36% change from the previous closing price of $54.28.

How does GSK stock forecast compare to its benchmarks?

GSK's stock forecast shows a -2.36% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (1.85%).

What is the breakdown of analyst ratings for GSK over the past three months?

  • March 2026: 0% Strong Buy, 12.50% Buy, 75.00% Hold, 12.50% Sell, 0% Strong Sell.
  • February 2026: 12.50% Strong Buy, 12.50% Buy, 62.50% Hold, 12.50% Sell, 0% Strong Sell.
  • January 2026: 12.50% Strong Buy, 12.50% Buy, 62.50% Hold, 12.50% Sell, 0% Strong Sell.

What is GSK’s EPS forecast?

GSK's average annual EPS forecast for its fiscal year ending in December 2024 is $3.07, marking a 155.83% increase from the reported $1.2 in 2023. Estimates for the following years are $3.25 in 2025, $3.65 in 2026, $3.98 in 2027, and $4.06 in 2028.

What is GSK’s revenue forecast?

GSK's average annual revenue forecast for its fiscal year ending in December 2024 is $38.7B, reflecting a 27.59% increase from the reported $30.33B in 2023. The forecast for 2025 is $40.25B, followed by $42.5B for 2026, $44.48B for 2027, and $45.07B for 2028.

What is GSK’s net income forecast?

GSK's net income forecast for the fiscal year ending in December 2024 stands at $12.66B, representing an 156.98% increase from the reported $4.93B in 2023. Projections indicate $13.33B in 2025, $12.56B in 2026, $16.26B in 2027, and $16.69B in 2028.